Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Assets (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Assets data on record, last reported at $231.1 million in Q3 2025.

  • For Q3 2025, Assets rose 91.63% year-over-year to $231.1 million; the TTM value through Sep 2025 reached $231.1 million, up 91.63%, while the annual FY2024 figure was $108.9 million, 70.2% up from the prior year.
  • Assets reached $231.1 million in Q3 2025 per ABEO's latest filing, down from $246.2 million in the prior quarter.
  • Across five years, Assets topped out at $246.2 million in Q2 2025 and bottomed at $38.8 million in Q3 2022.
  • Average Assets over 5 years is $101.3 million, with a median of $79.6 million recorded in 2021.
  • Peak YoY movement for Assets: plummeted 67.43% in 2022, then surged 150.24% in 2024.
  • A 5-year view of Assets shows it stood at $79.6 million in 2021, then decreased by 19.31% to $64.2 million in 2022, then fell by 0.33% to $64.0 million in 2023, then soared by 70.2% to $108.9 million in 2024, then skyrocketed by 112.15% to $231.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $231.1 million in Q3 2025, $246.2 million in Q2 2025, and $99.4 million in Q1 2025.